Receive our newsletter – data, insights and analysis delivered to you
June 17, 2009

J&J and Shire Win Exclusivity Case on Alzheimer’s Drug

Shire and Johnson & Johnson have won the backing of the European Court of Justice for data exclusivity against a generic rival, Generics UK, for the Alzheimer's drug Reminyl. The court ruled that a product approved in a country before it joined the EU, and not since upgraded, could

By cms admin

Shire and Johnson & Johnson have won the backing of the European Court of Justice for data exclusivity against a generic rival, Generics UK, for the Alzheimer’s drug Reminyl.

The court ruled that a product approved in a country before it joined the EU, and not since upgraded, could not be used for a generic product application.

Generics UK based its application for a generic version of Reminyl on the active ingredient Nivalin, which was approved in Austria in 1963 before the country joined the EU.

UK company Shire co-markets Reminyl in Europe with Janssen-Cilag AB, a unit of Johnson & Johnson.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU